Genome medicine: gene therapy for the millennium, 30 September-3 October 2001, Rome, Italy.

Abstract:

:The recent surge of DNA sequence information resulting from the efforts of agencies interested in deciphering the human genetic code has facilitated technological developments that have been critical in the identification of genes associated with numerous disease pathologies. In addition, these efforts have opened the door to the opportunity to develop novel genetic therapies to treat a broad range of inherited disorders. Through a joint effort by the University of Vermont, the University of Rome, Tor Vergata, University of Rome, La Sapienza, and the CSS Mendel Institute, Rome, an international meeting, 'Genome Medicine: Gene Therapy for the Millennium' was organized. This meeting provided a forum for the discussion of scientific and clinical advances stimulated by the explosion of sequence information generated by the Human Genome Project and the implications these advances have for gene therapy. The meeting had six sessions that focused on the functional evaluation of specific genes via biochemical analysis and through animal models, the development of novel therapeutic strategies involving gene targeting, artificial chromsomes, DNA delivery systems and non-embryonic stem cells, and on the ethical and social implications of these advances.

journal_name

Gene Ther

journal_title

Gene therapy

authors

Gruenert DC,Novelli G,Dallapiccola B,Colosimo A

doi

10.1038/sj.gt.3301740

keywords:

subject

Has Abstract

pub_date

2002-06-01 00:00:00

pages

653-7

issue

11

eissn

0969-7128

issn

1476-5462

journal_volume

9

pub_type

杂志文章
  • The proteasome metabolizes peptide-mediated nonviral gene delivery systems.

    abstract::The proteasome is a multisubunit cytosolic protein complex responsible for degrading cytosolic proteins. Several studies have implicated its involvement in the processing of viral particles used for gene delivery, thereby limiting the efficiency of gene transfer. Peptide-based nonviral gene delivery systems are suffic...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302575

    authors: Kim J,Chen CP,Rice KG

    更新日期:2005-11-01 00:00:00

  • Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo.

    abstract::Apo(a) is a very atherogenic plasma protein without apparent function, which is highly expressed in humans. The variation in plasma Lp(a) concentration among individuals is considerable. Approximately 10-15% of the white population exhibit plasma Lp(a) concentrations above the atherogenic cut-off value of approximatel...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301434

    authors: Frank S,Gauster M,Strauss J,Hrzenjak A,Kostner GM

    更新日期:2001-03-01 00:00:00

  • Foamy viral vector integration sites in SCID-repopulating cells after MGMTP140K-mediated in vivo selection.

    abstract::Foamy virus (FV) vectors are promising for hematopoietic stem cell (HSC) gene therapy but preclinical data on the clonal composition of FV vector-transduced human repopulating cells is needed. Human CD34(+) human cord blood cells were transduced with an FV vector encoding a methylguanine methyltransferase (MGMT)P140K ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2015.20

    authors: Olszko ME,Adair JE,Linde I,Rae DT,Trobridge P,Hocum JD,Rawlings DJ,Kiem HP,Trobridge GD

    更新日期:2015-07-01 00:00:00

  • Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA.

    abstract::RNA interference (RNAi) was reported to block hepatitis B virus (HBV) gene expression and replication in vitro and in vivo. However, it remains a technical challenge for RNAi-based therapy to achieve long-term and complete inhibition effects in chronic HBV infection, which presumably requires more extensive and unifor...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302846

    authors: Chen CC,Ko TM,Ma HI,Wu HL,Xiao X,Li J,Chang CM,Wu PY,Chen CH,Han JM,Yu CP,Jeng KS,Hu CP,Tao MH

    更新日期:2007-01-01 00:00:00

  • Use of protamine to augment adenovirus-mediated cancer gene therapy.

    abstract::Improving the therapeutic potential of adenoviral (Ad) suicide gene therapy has become an area of intense investigation since the inception of gene therapy strategies for cancer treatment. Poor efficiency of gene transfer to target tissues has become one of the most important limitations to Ad-based gene therapy. Sinc...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300987

    authors: Lanuti M,Kouri CE,Force S,Chang M,Amin K,Xu K,Blair I,Kaiser L,Albelda S

    更新日期:1999-09-01 00:00:00

  • Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.

    abstract::Adenoviral gene transfer to hematopoietic stem cells (HSCs)/progenitors would provide a new approach to the treatment of hematopoietic diseases and study of the hematopoietic system. We have previously reported that an adenovirus (Ad) vector composed of whole Ad serotype 35 (Ad35), which belongs to subgroup B, shows e...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302562

    authors: Sakurai F,Kawabata K,Yamaguchi T,Hayakawa T,Mizuguchi H

    更新日期:2005-10-01 00:00:00

  • Validation of recombinant Sendai virus in a non-natural host model.

    abstract::We have previously shown that recombinant Sendai virus (SeV) vector, derived from murine parainfluenza virus, is one of the most efficient vectors for airway gene transfer. We have also shown that SeV-mediated transfection on second administration, although reduced by 60% when compared with levels achieved after a sin...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2010.131

    authors: Griesenbach U,McLachlan G,Owaki T,Somerton L,Shu T,Baker A,Tennant P,Gordon C,Vrettou C,Baker E,Collie DD,Hasegawa M,Alton EW

    更新日期:2011-02-01 00:00:00

  • Efficient gene transfer of VSV-G pseudotyped retroviral vector to human brain tumor.

    abstract::A retroviral vector constructed from the murine leukemia virus (MLV) can only express transgenes in cells undergoing mitosis, indicating its suitability as a delivery vehicle for cancer gene therapy. However, the transduction efficiency (TE) of retroviruses embedding endogenous envelope proteins in human cancer cells ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301390

    authors: Lee H,Song JJ,Kim E,Yun CO,Choi J,Lee B,Kim J,Chang JW,Kim JH

    更新日期:2001-02-01 00:00:00

  • Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?

    abstract::Viral therapy of cancer includes strategies such as viral transduction of tumour cells with 'suicide genes', using viral infection to trigger immune-mediated tumour cell death and using oncolytic viruses for their direct anti-tumour action. However, problems still remain in terms of adequate viral delivery to tumours....

    journal_title:Gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/gt.2010.48

    authors: Pencavel T,Seth R,Hayes A,Melcher A,Pandha H,Vile R,Harrington KJ

    更新日期:2010-08-01 00:00:00

  • Progress and prospects: gene therapy for mitochondrial DNA disease.

    abstract::Defects of the mitochondrial genome cause a wide variety of clinical disorders. Except for rare cases where surgery or transplant is indicated, there is no effective treatment for patients. Genetic-based therapies are consequently being considered. On account of the difficulties associated with mitochondrial (mt) tran...

    journal_title:Gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/gt.2008.91

    authors: Kyriakouli DS,Boesch P,Taylor RW,Lightowlers RN

    更新日期:2008-07-01 00:00:00

  • Targeting of cell receptors and gene transfer efficiency: a balancing act.

    abstract::Vectors conjugated with ligands recognized by cell surface receptors are of interest for cystic fibrosis gene therapy since these vectors would allow cell-specific targeting. However, an efficient and specific uptake may be abrogated by a subsequent intracellular trafficking leading to an inefficient gene transfer. Th...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301738

    authors: Fajac I,Grosse S,Briand P,Monsigny M

    更新日期:2002-06-01 00:00:00

  • Targeted beta-globin gene conversion in human hematopoietic CD34(+ )and Lin(-)CD38(-)cells.

    abstract::Chimeric oligonucleotides have been used successfully to correct point and frameshift mutations in several cell types, as well as in animal and plant models. However, their application to primitive human blood cells has been limited. In this investigation, chimeric oligonucleotides designed to direct a site-specific n...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301610

    authors: Liu H,Agarwal S,Kmiec E,Davis BR

    更新日期:2002-01-01 00:00:00

  • The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication.

    abstract::The bystander effect (BSE) is an interesting and important property of the herpes thymidine kinase/ganciclovir (hTK/GCV) system of gene therapy for cancer. With the BSE, not only are the hTK expressing cells killed upon ganciclovir (GCV) exposure but also neighboring wild-type tumor cells. On testing a large number of...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300784

    authors: Touraine RL,Ishii-Morita H,Ramsey WJ,Blaese RM

    更新日期:1998-12-01 00:00:00

  • Widespread transduction of astrocytes and neurons in the mouse central nervous system after systemic delivery of a self-complementary AAV-PHP.B vector.

    abstract::Until recently, adeno-associated virus 9 (AAV9) was considered the AAV serotype most effective in crossing the blood-brain barrier (BBB) and transducing cells of the central nervous system (CNS), following systemic injection. However, a newly engineered capsid, AAV-PHP.B, is reported to cross the BBB at even higher ef...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/s41434-018-0005-z

    authors: Rincon MY,de Vin F,Duqué SI,Fripont S,Castaldo SA,Bouhuijzen-Wenger J,Holt MG

    更新日期:2018-04-01 00:00:00

  • A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes.

    abstract::Genetic engineering of T lymphocytes for adoptive clinical immunotherapy calls for efficient gene transduction methods. Therefore, a transient retroviral gene transduction system 'STITCH' was developed comprising pSTITCH retroviral vector encoding the transgene, plasmids encoding Moloney murine leukemia virus gag/pol ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300696

    authors: Weijtens ME,Willemsen RA,Hart EH,Bolhuis RL

    更新日期:1998-09-01 00:00:00

  • A novel, membrane receptor-based retroviral vector for Fanconi anemia group C gene therapy.

    abstract::Retroviral vectors are effective shuttle systems by introducing therapeutically relevant genes stably into the genome of proliferating cells. The majority of vectors applied for research or clinical applications use neomycin for cell selection and identification. To circumvent the time consuming and potentially toxic ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300384

    authors: Machl AW,Planitzer S,Kubbies M

    更新日期:1997-04-01 00:00:00

  • Apical barriers to airway epithelial cell gene transfer with amphotropic retroviral vectors.

    abstract::Gene transfer to airway epithelia with amphotropic pseudotyped retroviral vectors is inefficient following apical vector application. To better understand this inefficiency, we localized the expression of Pit2, the amphotropic receptor, in polarized human airway epithelia. Pit2 was expressed on both the apical and bas...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301714

    authors: Wang G,Williams G,Xia H,Hickey M,Shao J,Davidson BL,McCray PB

    更新日期:2002-07-01 00:00:00

  • Continuous secretion of human soluble CD4 in mice transplanted with genetically modified cells.

    abstract::Somatic transgenesis can be used to confer endogenous production of proteins with therapeutic properties. One such product, recombinant soluble human CD4 (sCD4), has been shown to be an efficient inhibitor of human immunodeficiency virus 1 (HIV-1) in vitro, but its too short half-life in vivo has impaired long-term cl...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:

    authors: Valere T,Bohl D,Klatzmann D,Danos O,Sonigo P,Heard JM

    更新日期:1995-05-01 00:00:00

  • Evaluation of recombinant alphaviruses as vectors in gene therapy.

    abstract::Alphavirus vectors based on Sindbis virus and Semliki Forest virus (SFV) were characterized as potential gene transfer vectors. Initial studies were performed using vectors engineered to transfer either lacZ or green fluorescent protein (GFP). High levels of gene transfer were achieved in human primary fibroblasts, BH...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301122

    authors: Wahlfors JJ,Zullo SA,Loimas S,Nelson DM,Morgan RA

    更新日期:2000-03-01 00:00:00

  • Chitosan-plasmid nanoparticle formulations for IM and SC delivery of recombinant FGF-2 and PDGF-BB or generation of antibodies.

    abstract::Growth factor therapy is an emerging treatment modality that enhances tissue vascularization, promotes healing and regeneration and can treat a variety of inflammatory diseases. Both recombinant human growth factor proteins and their gene therapy are in human clinical trials to heal chronic wounds. As platelet-derived...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2009.60

    authors: Jean M,Smaoui F,Lavertu M,Méthot S,Bouhdoud L,Buschmann MD,Merzouki A

    更新日期:2009-09-01 00:00:00

  • Improved safety and titre of murine leukaemia virus (MLV)-based retroviral vectors.

    abstract::Many retroviral vectors based on murine leukaemia virus (MLV) contain the first 420 nucleotides of the gag gene, as this was reported to increase vector titre by increasing the efficiency of RNA packaging. In this study, deletion of this gag sequence from its original location did not decrease the titre of two retrovi...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301081

    authors: Zhao Y,Low W,Collins MK

    更新日期:2000-02-01 00:00:00

  • Progress and prospects: oligonucleotide-directed gene modification in mouse embryonic stem cells: a route to therapeutic application.

    abstract::Gene targeting by single-stranded oligodeoxyribonucleotides (ssODNs) is a promising technique for introducing site-specific sequence alterations without affecting the genomic organization of the target locus. Here, we discuss the significant progress that has been made over the last 5 years in unraveling the mechanism...

    journal_title:Gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/gt.2010.161

    authors: Aarts M,te Riele H

    更新日期:2011-03-01 00:00:00

  • In utero administration of Ad5 and AAV pseudotypes to the fetal brain leads to efficient, widespread and long-term gene expression.

    abstract::The efficient delivery of genetic material to the developing fetal brain represents a powerful research tool and a means to supply therapy in a number of neonatal lethal neurological disorders. In this study, we have delivered vectors based upon adenovirus serotype 5 (Ad5) and adeno-associated virus (AAV) pseudotypes ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2011.157

    authors: Rahim AA,Wong AM,Ahmadi S,Hoefer K,Buckley SM,Hughes DA,Nathwani AN,Baker AH,McVey JH,Cooper JD,Waddington SN

    更新日期:2012-09-01 00:00:00

  • A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.

    abstract::The GM2-gangliosidoses are neurological diseases causing premature death, thus developing effective treatment protocols is urgent. GM2-gangliosidoses result from deficiency of a lysosomal enzyme β-hexosaminidase (Hex) and subsequent accumulation of GM2 gangliosides. Genetic changes in HEXA, encoding the Hex α subunit,...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/s41434-019-0120-5

    authors: Ou L,Przybilla MJ,Tăbăran AF,Overn P,O'Sullivan MG,Jiang X,Sidhu R,Kell PJ,Ory DS,Whitley CB

    更新日期:2020-05-01 00:00:00

  • Herpesvirus microRNAs for use in gene therapy immune-evasion strategies.

    abstract::Transplantation of allogeneic cells as well as of genetically corrected autologous cells are potent approaches to restore cellular functions in patients suffering from genetic diseases. The recipient's immune responses against non-self-antigens may compromise the survival of the grafted cells. Recipients of the graft ...

    journal_title:Gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/gt.2017.37

    authors: Bots STF,Hoeben RC

    更新日期:2017-07-01 00:00:00

  • Generation of human TRIM5alpha mutants with high HIV-1 restriction activity.

    abstract::Rhesus macaque tripartite motif (TRIM)5alpha potently inhibits early stages of human immunodeficiency virus (HIV)-1 replication, while the human orthologue has little effect on this virus. We used PCR-based random mutagenesis to construct a large library of human TRIM5alpha variants containing mutations in the PRYSPRY...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2010.40

    authors: Pham QT,Bouchard A,Grütter MG,Berthoux L

    更新日期:2010-07-01 00:00:00

  • Evidence for localization of biologically active recombinant retroviral vector to lymph nodes in mice injected intramuscularly.

    abstract::We have developed a novel gene transfer drug, HIV-IT(V), for the treatment of HIV infection in humans. HIV-IT(V) is a retroviral vector encoding the HIV-1 IIIB env and rev genes and a neomycin resistance marker gene (neor). We have recently reported that HIV-IT(V) administered intramuscularly to male mice localizes pr...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:

    authors: Kamantigue E,Edwards W 3rd,Chada S,Brumm D,Austin M,Irwin M,Mento S,Kowal K,Sajjadi N

    更新日期:1996-02-01 00:00:00

  • Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo.

    abstract::Cytomegalovirus (CMV) promoter is often present in recombinant adenovirus vectors (AdVs) suitable for gene therapy, ensuring high levels of transgene production in a wide range of hosts. Despite this characteristic, the presence of the AdV genome in target cells and tissues typically lasts longer than transgene produc...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301296

    authors: Gaetano C,Catalano A,Palumbo R,Illi B,Orlando G,Ventoruzzo G,Serino F,Capogrossi MC

    更新日期:2000-10-01 00:00:00

  • An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery.

    abstract::Adenovirus (Ad) vectors are of utility for many therapeutic applications. Strategies have been developed to alter adenoviral tropism to achieve a cell-specific gene delivery capacity employing fiber modifications allowing genetic incorporation of targeting motifs. In this regard, single chain antibodies (scFv) represe...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302603

    authors: Hedley SJ,Auf der Maur A,Hohn S,Escher D,Barberis A,Glasgow JN,Douglas JT,Korokhov N,Curiel DT

    更新日期:2006-01-01 00:00:00

  • Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.

    abstract::Dendritic cell (DC)-based vaccine approaches are being actively evaluated for developing immunotherapeutic agents against cancers. In this study, we investigated the use of engineered DCs expressing transgenic tumor-associated antigen hgp100 and the regulatory cytokine interleukin-21, namely DC-hgp100/mIL-21, as a the...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2014.12

    authors: Aravindaram K,Wang PH,Yin SY,Yang NS

    更新日期:2014-05-01 00:00:00